Shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) traded down 10% on Wednesday . The stock traded as low as $153.98 and last traded at $157.86, 733,800 shares traded hands during mid-day trading. An increase of 86% from the average session volume of 395,121 shares. The stock had previously closed at $175.31.
A number of equities research analysts have weighed in on the stock. BidaskClub downgraded shares of Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $320.00 price target (up from $314.00) on shares of Reata Pharmaceuticals in a report on Thursday, February 20th. ValuEngine downgraded shares of Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Robert W. Baird reissued an “outperform” rating and issued a $283.00 price target (up from $245.00) on shares of Reata Pharmaceuticals in a report on Thursday, February 20th. Finally, Zacks Investment Research raised shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Reata Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $278.13.
The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.49 and a current ratio of 3.49. The company has a market capitalization of $4.72 billion, a price-to-earnings ratio of -15.74 and a beta of 2.52. The stock’s fifty day simple moving average is $206.80 and its two-hundred day simple moving average is $173.54.Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($5.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.21) by ($3.70). Reata Pharmaceuticals had a negative net margin of 1,094.28% and a negative return on equity of 766.88%. The business had revenue of $2.67 million during the quarter, compared to analyst estimates of $8.04 million. During the same period in the previous year, the company posted ($0.86) earnings per share. Reata Pharmaceuticals’s revenue was down 68.4% compared to the same quarter last year. On average, equities analysts anticipate that Reata Pharmaceuticals Inc will post -8.47 EPS for the current fiscal year.
In other Reata Pharmaceuticals news, VP Jason Douglas Wilson sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $203.26, for a total transaction of $2,032,600.00. Following the completion of the sale, the vice president now directly owns 17,350 shares of the company’s stock, valued at $3,526,561. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Elaine Castellanos sold 2,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $194.32, for a total transaction of $388,640.00. Following the sale, the chief accounting officer now directly owns 17,146 shares of the company’s stock, valued at $3,331,810.72. The disclosure for this sale can be found here. 34.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC lifted its stake in Reata Pharmaceuticals by 0.8% during the fourth quarter. ProShare Advisors LLC now owns 8,988 shares of the company’s stock valued at $1,837,000 after buying an additional 71 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Reata Pharmaceuticals by 7.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,333 shares of the company’s stock valued at $273,000 after purchasing an additional 93 shares during the period. Optimum Investment Advisors increased its holdings in shares of Reata Pharmaceuticals by 24.8% in the 4th quarter. Optimum Investment Advisors now owns 1,007 shares of the company’s stock valued at $206,000 after purchasing an additional 200 shares during the period. US Bancorp DE increased its holdings in shares of Reata Pharmaceuticals by 1,533.3% in the 4th quarter. US Bancorp DE now owns 245 shares of the company’s stock valued at $50,000 after purchasing an additional 230 shares during the period. Finally, California State Teachers Retirement System increased its holdings in shares of Reata Pharmaceuticals by 1.0% in the 3rd quarter. California State Teachers Retirement System now owns 31,272 shares of the company’s stock valued at $2,511,000 after purchasing an additional 322 shares during the period. 67.14% of the stock is owned by institutional investors.
Reata Pharmaceuticals Company Profile (NASDAQ:RETA)
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich’s ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
